Comparison of remimazolam and dexmedetomidine as an adjuvant in remifentanil-based anesthesia

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0007473

Enrollment

Registered

2022-06-30

Start date

2022-07-05

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : 1. Patients under total intravenous anesthesia are divided into three groups (administering remimazolam, dexmedetomidine as an anesthetic adjuvant, and a control group administering normal sali

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: The subjects of the study were ASA class I patients who underwent breast surgery under total intravenous anesthesia at Konkuk University Hospital.

Exclusion criteria

Exclusion criteria: The exclusion criteria were 1. emergency surgery, 2. allergy to egg or soybean oil, 3. history of drug misuse, 4. taking other opioids, 5. other surgeries at the same time, 6. lactose intorelance, and 7. severe liver failure.

Design outcomes

Primary

Measure	Time frame
Usage of propofol	—

Secondary

Measure	Time frame
Time to awake from anesthesia;Postoperative nausea and vomiting;Total intraoperative vasopressor requirement (including phenylephrine)	—

Countries

Korea, Republic of

Contacts

Public ContactSeung wan Hong

Konkuk University Medical Center

20150077@kuh.ac.kr+82-2-2030-5448

Outcome results